Profile cover photo
Profile photo
Amarantus BioScience Holdings, Inc.
43 followers -
Amarantus BioScience Holdings (OTCQB: AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology, regenerative medicine and orphan diseases.
Amarantus BioScience Holdings (OTCQB: AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology, regenerative medicine and orphan diseases.

43 followers
About
Amarantus BioScience Holdings, Inc.'s posts

Post has attachment
Amarantus today announced the publication of a 16-subject clinical study of Engineered Skin Substitute ("ESS," or "Permaderm™") in children with life-threatening severe burns. In this study, ESS was compared with the standard of care (split-thickness autograft "AG") for treating full-thickness (dermal and epidermal layers of skin) life-threatening pediatric severe burns covering a total body surface area (TBSA) of 50% or greater. The article entitled "Randomized, Paired-Site Comparison of Autologous Engineered Skin Substitutes and Split-Thickness Skin Graft for Closure of Extensive, Full-Thickness Burns" was published online in the July edition of the Journal of Burn Care and Research (Boyce, et al, 2016). For a summary of the data and a link to the publication, click here: http://bit.ly/2aUoDup

Post has attachment
Amarantus BioScience Holdings, Inc. today announced that the current Good Manufacturing Practices (cGMP) manufacturing process for its Engineered Skin Substitute (ESS) program is now qualified at Lonza Walkersville, Inc., a premier contract manufacturer providing cell and tissue-based products for clinical development. Reaching this milestone signifies that Amarantus is now positioned to supply ESS for its planned opening of the 10-patient, randomized, placebo-controlled, open-label Phase 2 clinical trial for the treatment of adult patients (ages 18-40 years old) with deep-partial and full-thickness thermal burns covering ≥50% of total body surface area (TBSA). The Company will open enrollment at the first site, the U.S. Army’s Institute for Surgical Research (ISR) at Fort Sam Houston in Texas, under a Collaborative Research & Development Agreement (CRADA). Two additional civilian sites will be opened after ISR to accelerate enrollment of the study. For additional study information, read the full press release available here: http://bit.ly/1UnzIRk

Post has attachment

Post has attachment
Amarantus today announced that President & CEO Gerald E. Commissiong will be presenting at two upcoming investor conferences: SeeThruEquity MicroCap Conference on May 31st, 2016 at 3:00pm and Marcum MicroCap Conference on June 1st, 2016 at 3:00pm. Additional details available here: http://bit.ly/1WQud3o

Post has attachment
PDF Blog contributor Beth Vernaleo, Ph.D. discusses Eltoprazine and its recent orphan drug status granted by the FDA in a new post. Dr. Vernaleo explains that if Eltoprazine is approved, it would fill an important unmet medical need for patients. Read her full piece here: http://bit.ly/1Wp43EU

Post has attachment

Post has attachment

Post has attachment

Post has attachment

Post has attachment
Wait while more posts are being loaded